The State of Immunotherapy in Hepatobiliary Cancers
Hepatobiliary cancers, including hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and gallbladder carcinoma (GBC), are lethal cancers with limited therapeutic options. Curative-intent treatment typically involves surgery, yet recurrence is common and many patients present with advanced dise...
Main Authors: | Farhan Z. Ilyas, Joal D. Beane, Timothy M. Pawlik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/8/2096 |
Similar Items
-
Advances in Targeted Immunotherapy for Hepatobiliary Cancers
by: Samantha M. Ruff, et al.
Published: (2022-11-01) -
Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010–2018
by: Florian Hucke, et al.
Published: (2022-06-01) -
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
by: Alice Boilève, et al.
Published: (2021-05-01) -
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update
by: Christo Kole, et al.
Published: (2020-10-01) -
The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma
by: Liliana Montella, et al.
Published: (2021-07-01)